Business Context and Reporting Period
PDS Biotechnology Corporation (PDSB), a Delaware corporation, filed this Form 8-K on September 22, 2026. The report addresses a significant clinical development event rather than routine financial reporting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a Current Report focused on a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the publication of clinical trial results in a peer-reviewed journal. On September 22, 2026, the company announced the publication of results from the Phase 2 VERSATILE-002 trial in the September 17, 2026, issue of JAMA Oncology. The study evaluated PDS0101, an HPV16-targeted T cell immunotherapy, in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or a discussion of risks and contingencies beyond the context of the clinical trial publication. The primary focus is the dissemination of the nonrandomized clinical trial data.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for specific efficacy and safety data from the VERSATILE-002 trial.
- Review the published article in JAMA Oncology to confirm the peer-reviewed findings regarding PDS0101 and pembrolizumab.
- Check subsequent filings for any regulatory decisions or development plans triggered by these Phase 2 results.
- Confirm the company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not provide liquidity data.